American Well Corporation (AMWL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Amwell outlined its strategic focus on becoming a technology-enabled care platform, aiming for breakeven by 2026 through significant cost structure improvements and investments in AI. The company emphasizes its unique holistic infrastructure, which integrates diverse clinical programs to provide a singular, white-label experience for large clients, including major payers and the U.S. military (DHA contract). Amwell plans to drive future growth by increasing engagement within its 80-90 million covered lives and securing new clients, leveraging its proven ability to deliver demonstrable ROI and harness AI for improved access, cost efficiency, and clinical outcomes in healthcare.

Analysis

American Well Corporation (Amwell) is executing a strategic pivot to a technology-enabled care platform, moving away from ancillary services to focus on its core software infrastructure for large enterprise clients like payers and government entities. Management has established a clear target of achieving breakeven by 2026, supported by aggressive cost-cutting measures that have reduced employee headcount from over 1,000 to approximately 650. The financial model is shifting toward higher-margin, SaaS-like revenues generated from a revenue-share on third-party clinical programs integrated into its platform, which management states can yield margins exceeding 90%. This open, integrated platform is presented as Amwell's key differentiator in a fragmented market, offering large sponsors a single, white-labeled solution to manage a complex ecosystem of disparate clinical services and generate unified ROI reporting.

The contract with the U.S. military's Defense Health Agency (DHA) serves as a critical validation of the platform's scalability, security, and execution capability, having been delivered on time and on budget. While a one-year extension was granted, the decision not to expand certain service modules enterprise-wide—which management attributes to government financial considerations—highlights a potential risk in contract scope and dependency on client budgets. Nevertheless, the company views this deployment as a significant competitive moat and a repeatable model for pursuing other large government contracts. Future growth is predicated on two main levers: first, driving deeper utilization and service adoption within its existing covered base of 80-90 million lives ("same-store growth"), and second, leveraging its AI investments to fundamentally alter the cost structure of care delivery. The recent hiring of key executives from Amazon underscores a deep commitment to using AI to enhance patient matching, improve clinical and financial outcomes, and provide the demonstrable ROI that clients are increasingly demanding.

Key Decisions for Investors

• Investors should monitor Amwell's progress toward its stated 2026 breakeven target, focusing on gross margin expansion as a key indicator of the successful shift towards higher-value, SaaS-like platform revenue.
• The status of the DHA contract is a critical bellwether; watch for the potential enterprise-wide expansion of previously delayed modules and the company's ability to convert this flagship win into new large-scale government or commercial contracts.
• Evaluate the tangible impact of AI investments over the next 12-18 months by looking for specific product releases and client-reported metrics that validate claims of improved cost-efficiency and ROI.
• Track key performance indicators related to utilization and engagement within the existing 80-90 million covered lives, as success in driving this 'same-store growth' is the primary near-term revenue catalyst.